Publicaciones en colaboración con investigadores/as de Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer (9)

2022

  1. Novel adcs and strategies to overcome resistance to anti-her2 adcs

    Cancers, Vol. 14, Núm. 1

2020

  1. Antitumoral properties of the nutritional supplement ocoxin oral solution: A comprehensive review

    Nutrients, Vol. 12, Núm. 9, pp. 1-18

2019

  1. Central role of cell cycle regulation in the antitumoral action of ocoxin

    Nutrients, Vol. 11, Núm. 5

  2. TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells

    Cancer Letters, Vol. 453, pp. 34-44

2017

  1. Resistance to the antibody–drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity

    Cancer Research, Vol. 77, Núm. 17, pp. 4639-4651

2016

  1. Antitumoral effect of Ocoxin on acute myeloid leukemia

    Oncotarget, Vol. 7, Núm. 5, pp. 6231-6242

2014

  1. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 Inhibition as an antimyeloma strategy

    Molecular Cancer Therapeutics, Vol. 13, Núm. 2, pp. 504-516

2012

  1. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

    Leukemia, Vol. 26, Núm. 8, pp. 1862-1869

2008

  1. Neuregulins and cancer

    Clinical Cancer Research, Vol. 14, Núm. 11, pp. 3237-3241